SCIENTIFIC BACKGROUND

ABL1, ABL2, AKT1, AKT2, ALK, ANKRD26, APC, AR, ARAF, ASXL1, ATM, ATRX, B2M, BAP1, BARD1, BCL2, BCL6, BCOR, BCORL1, BCR, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBFB, CBL, CBLB, CBLC, CCND1, CCND2, CCND3, CCNE1, CD274, CD74, CDC25C, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK2, CIC, CSF1R, CSF3R, CTLA4, CTNNB1, CUX1, CXCR4, DCK, DDR2, DDX41, DEK, DHX15, DICER1, DNMT3A, DUSP22, EGFR, EIF1AX, EPCAM, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ESR1, ETNK1, ETV1, ETV4, ETV6, EWSR1, EZH2, FANCA, FBXW7, FGF13, FGF19, FGF2, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FRS2, FUBP1, GATA1, GATA2, GATA3, GNA11, GNAQ, GNAS, H3F3A, HDAC2, HOXB13, HRAS, IDH1, IDH2, IKZF1, IL3, INHA, INSRR, IRF4, JAK1, JAK2, JAK3, KDM6A, KDR, KEAP1, KIT, KMT2A, KMT2C, KMT2D, KRAS, LUC7L2, MALT1, MAP2K1, MAP2K2, MAP3K1, MDM2, MECOM, MET, MITF, MLH1, MLLT3, MPL, MRE11, MSH2, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, MYH11, MYOD1, NBN, NCOA3, NF1, NF2, NFE2L2, NOTCH1, NPM1, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUP214, NUTM1, PALB2, PARP1, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PGR, PHF6, PIK3CA, PIK3CB, PIK3R1, PML, PMS2, POLD1, POLE, PPM1D, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51C, RAD51D, RAF1, RARA, RB1, RBBP6, RET, RNF43, ROS1, RPS14, RUNX1, RUNX1T1, SETBP1, SF3B1, SH2B3, SLC29A1, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SOX10, SPOP, SRSF2, STAG2, STAT3, STAT5B, STK11, SUZ12, TCF3, TCL1A, TERT, TET2, TMPRSS2, TP53, TSC1, TSC2, U2AF1, VEGFA, VHL, WT1, XPO1, ZRSR2

Category:

Scientific Background

The NeoThetis Pan-Cancer Plus panel analyses 222 genes associated with different types of cancers. It can help identify genetic alterations that can be responsible for cancer development and therapy resistance in solid tumors. The clinical significance of the genes tested has been previously emphasized by professional bodies including NCCN and ESMO. Depending on the type of the cancer and the genetic alterations identified, different FDA/EMA approved drugs as well as eligible clinical trials are available.

 

Microsatellite instability (MSI) immunotherapy biomarker is also tested in this panel. FDA/EMA approved immunotherapies, such as pembrolizumab, are also available for patients with MSI-high status depending on their type of cancer.

 

blood-based Tumor Mutational Burden (bTMB) immunotherapy biomarker is also tested in this panel. bTMB is tumor agnostic and is applicable for all solid tumors, including rare types. It can guide healthcare providers to identify patients who might benefit from immunotherapy.

 

How many genes are tested in this panel?

222 genes

 

Recommendations by professional bodies

Professional bodies such as ESMO recommend liquid biopsy genetic testing for different types of cancer and in different circumstances; such as when tissue biopsy is not feasible or when fast turnaround results are required (Pascual et al., 2022; ESMO recommendations).

For more details on recommendations please visit our cancer-specific panels.

 

References and more information: 

Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6. PMID: 35809752.

GENES

ABL1, ABL2, AKT1, AKT2, ALK, ANKRD26, APC, AR, ARAF, ASXL1, ATM, ATRX, B2M, BAP1, BARD1, BCL2, BCL6, BCOR, BCORL1, BCR, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBFB, CBL, CBLB, CBLC, CCND1, CCND2, CCND3, CCNE1, CD274, CD74, CDC25C, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK2, CIC, CSF1R, CSF3R, CTLA4, CTNNB1, CUX1, CXCR4, DCK, DDR2, DDX41, DEK, DHX15, DICER1, DNMT3A, DUSP22, EGFR, EIF1AX, EPCAM, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ESR1, ETNK1, ETV1, ETV4, ETV6, EWSR1, EZH2, FANCA, FBXW7, FGF13, FGF19, FGF2, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FRS2, FUBP1, GATA1, GATA2, GATA3, GNA11, GNAQ, GNAS, H3F3A, HDAC2, HOXB13, HRAS, IDH1, IDH2, IKZF1, IL3, INHA, INSRR, IRF4, JAK1, JAK2, JAK3, KDM6A, KDR, KEAP1, KIT, KMT2A, KMT2C, KMT2D, KRAS, LUC7L2, MALT1, MAP2K1, MAP2K2, MAP3K1, MDM2, MECOM, MET, MITF, MLH1, MLLT3, MPL, MRE11, MSH2, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, MYH11, MYOD1, NBN, NCOA3, NF1, NF2, NFE2L2, NOTCH1, NPM1, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUP214, NUTM1, PALB2, PARP1, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PGR, PHF6, PIK3CA, PIK3CB, PIK3R1, PML, PMS2, POLD1, POLE, PPM1D, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51C, RAD51D, RAF1, RARA, RB1, RBBP6, RET, RNF43, ROS1, RPS14, RUNX1, RUNX1T1, SETBP1, SF3B1, SH2B3, SLC29A1, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SOX10, SPOP, SRSF2, STAG2, STAT3, STAT5B, STK11, SUZ12, TCF3, TCL1A, TERT, TET2, TMPRSS2, TP53, TSC1, TSC2, U2AF1, VEGFA, VHL, WT1, XPO1, ZRSR2

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact ...

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more